Treatment strategies for central nervous system infections: An update

Ying Ching Tan, Arshdeep Kaur Gill, Kwang Sik Kim

Research output: Contribution to journalArticle

Abstract

Introduction: Central nervous system infection continues to be an important cause of mortality and morbidity worldwide. Our incomplete knowledge on the pathogenesis of how meningitis-causing pathogens cause CNS infection and emergence of antimicrobial resistance has contributed to the mortality and morbidity. An early empiric antibiotic treatment is critical for the management of patients with bacterial meningitis, but early recognition of bacterial meningitis continues to be a challenge. Areas covered: This review gives an overview on current therapeutic strategies for CNS infection with a focus on recent literature since 2010 on bacterial meningitis. Bacterial meningitis is a medical emergency, requiring early recognition and treatment. The selection of appropriate empiric antimicrobial regimen, after incorporating the epidemiology of bacterial meningitis, impact of vaccination, emergence of antimicrobial-resistant bacteria, role of adjunctive therapy and the current knowledge on the pathogenesis of meningitis and associated neuronal injury are covered. Expert opinion: Prompt treatment of bacterial meningitis with an appropriate antibiotic is essential. Optimal antimicrobial treatment of bacterial meningitis requires bactericidal agents able to penetrate the blood-brain barrier, with efficacy in cerebrospinal fluid. Emergence of CNS-infecting pathogens with resistance to conventional antibiotics has been increasingly recognized, but development of new antibiotics has been limited. More complete understanding of the microbial and host factors that are involved in the pathogenesis of bacterial meningitis and associated neurologic sequelae is likely to help in developing new strategies for the prevention and therapy of bacterial meningitis.

Original languageEnglish (US)
Pages (from-to)187-203
Number of pages17
JournalExpert Opinion on Pharmacotherapy
Volume16
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

Central Nervous System Infections
Bacterial Meningitides
Anti-Bacterial Agents
Therapeutics
Meningitis
Morbidity
Mortality
Expert Testimony
Infection
Blood-Brain Barrier
Nervous System
Cerebrospinal Fluid
Vaccination
Epidemiology
Emergencies
Bacteria

Keywords

  • Antimicrobial resistance
  • Antimicrobial therapy
  • Bacterial meningitis
  • Blood-brain barrier
  • Cerebrospinal fluid
  • Dexamethasone
  • Escherichia coli
  • Group B streptococcus
  • Haemophilus influenzae type b
  • Listeria monocytogenes
  • Neisseria meningitidis
  • Neurologic sequelae
  • Streptococcus pneumoniae

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Treatment strategies for central nervous system infections : An update. / Tan, Ying Ching; Gill, Arshdeep Kaur; Kim, Kwang Sik.

In: Expert Opinion on Pharmacotherapy, Vol. 16, No. 2, 01.02.2015, p. 187-203.

Research output: Contribution to journalArticle

Tan, Ying Ching ; Gill, Arshdeep Kaur ; Kim, Kwang Sik. / Treatment strategies for central nervous system infections : An update. In: Expert Opinion on Pharmacotherapy. 2015 ; Vol. 16, No. 2. pp. 187-203.
@article{c423abb7a0e74f0ab912f19167daf28e,
title = "Treatment strategies for central nervous system infections: An update",
abstract = "Introduction: Central nervous system infection continues to be an important cause of mortality and morbidity worldwide. Our incomplete knowledge on the pathogenesis of how meningitis-causing pathogens cause CNS infection and emergence of antimicrobial resistance has contributed to the mortality and morbidity. An early empiric antibiotic treatment is critical for the management of patients with bacterial meningitis, but early recognition of bacterial meningitis continues to be a challenge. Areas covered: This review gives an overview on current therapeutic strategies for CNS infection with a focus on recent literature since 2010 on bacterial meningitis. Bacterial meningitis is a medical emergency, requiring early recognition and treatment. The selection of appropriate empiric antimicrobial regimen, after incorporating the epidemiology of bacterial meningitis, impact of vaccination, emergence of antimicrobial-resistant bacteria, role of adjunctive therapy and the current knowledge on the pathogenesis of meningitis and associated neuronal injury are covered. Expert opinion: Prompt treatment of bacterial meningitis with an appropriate antibiotic is essential. Optimal antimicrobial treatment of bacterial meningitis requires bactericidal agents able to penetrate the blood-brain barrier, with efficacy in cerebrospinal fluid. Emergence of CNS-infecting pathogens with resistance to conventional antibiotics has been increasingly recognized, but development of new antibiotics has been limited. More complete understanding of the microbial and host factors that are involved in the pathogenesis of bacterial meningitis and associated neurologic sequelae is likely to help in developing new strategies for the prevention and therapy of bacterial meningitis.",
keywords = "Antimicrobial resistance, Antimicrobial therapy, Bacterial meningitis, Blood-brain barrier, Cerebrospinal fluid, Dexamethasone, Escherichia coli, Group B streptococcus, Haemophilus influenzae type b, Listeria monocytogenes, Neisseria meningitidis, Neurologic sequelae, Streptococcus pneumoniae",
author = "Tan, {Ying Ching} and Gill, {Arshdeep Kaur} and Kim, {Kwang Sik}",
year = "2015",
month = "2",
day = "1",
doi = "10.1517/14656566.2015.973851",
language = "English (US)",
volume = "16",
pages = "187--203",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Treatment strategies for central nervous system infections

T2 - An update

AU - Tan, Ying Ching

AU - Gill, Arshdeep Kaur

AU - Kim, Kwang Sik

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Introduction: Central nervous system infection continues to be an important cause of mortality and morbidity worldwide. Our incomplete knowledge on the pathogenesis of how meningitis-causing pathogens cause CNS infection and emergence of antimicrobial resistance has contributed to the mortality and morbidity. An early empiric antibiotic treatment is critical for the management of patients with bacterial meningitis, but early recognition of bacterial meningitis continues to be a challenge. Areas covered: This review gives an overview on current therapeutic strategies for CNS infection with a focus on recent literature since 2010 on bacterial meningitis. Bacterial meningitis is a medical emergency, requiring early recognition and treatment. The selection of appropriate empiric antimicrobial regimen, after incorporating the epidemiology of bacterial meningitis, impact of vaccination, emergence of antimicrobial-resistant bacteria, role of adjunctive therapy and the current knowledge on the pathogenesis of meningitis and associated neuronal injury are covered. Expert opinion: Prompt treatment of bacterial meningitis with an appropriate antibiotic is essential. Optimal antimicrobial treatment of bacterial meningitis requires bactericidal agents able to penetrate the blood-brain barrier, with efficacy in cerebrospinal fluid. Emergence of CNS-infecting pathogens with resistance to conventional antibiotics has been increasingly recognized, but development of new antibiotics has been limited. More complete understanding of the microbial and host factors that are involved in the pathogenesis of bacterial meningitis and associated neurologic sequelae is likely to help in developing new strategies for the prevention and therapy of bacterial meningitis.

AB - Introduction: Central nervous system infection continues to be an important cause of mortality and morbidity worldwide. Our incomplete knowledge on the pathogenesis of how meningitis-causing pathogens cause CNS infection and emergence of antimicrobial resistance has contributed to the mortality and morbidity. An early empiric antibiotic treatment is critical for the management of patients with bacterial meningitis, but early recognition of bacterial meningitis continues to be a challenge. Areas covered: This review gives an overview on current therapeutic strategies for CNS infection with a focus on recent literature since 2010 on bacterial meningitis. Bacterial meningitis is a medical emergency, requiring early recognition and treatment. The selection of appropriate empiric antimicrobial regimen, after incorporating the epidemiology of bacterial meningitis, impact of vaccination, emergence of antimicrobial-resistant bacteria, role of adjunctive therapy and the current knowledge on the pathogenesis of meningitis and associated neuronal injury are covered. Expert opinion: Prompt treatment of bacterial meningitis with an appropriate antibiotic is essential. Optimal antimicrobial treatment of bacterial meningitis requires bactericidal agents able to penetrate the blood-brain barrier, with efficacy in cerebrospinal fluid. Emergence of CNS-infecting pathogens with resistance to conventional antibiotics has been increasingly recognized, but development of new antibiotics has been limited. More complete understanding of the microbial and host factors that are involved in the pathogenesis of bacterial meningitis and associated neurologic sequelae is likely to help in developing new strategies for the prevention and therapy of bacterial meningitis.

KW - Antimicrobial resistance

KW - Antimicrobial therapy

KW - Bacterial meningitis

KW - Blood-brain barrier

KW - Cerebrospinal fluid

KW - Dexamethasone

KW - Escherichia coli

KW - Group B streptococcus

KW - Haemophilus influenzae type b

KW - Listeria monocytogenes

KW - Neisseria meningitidis

KW - Neurologic sequelae

KW - Streptococcus pneumoniae

UR - http://www.scopus.com/inward/record.url?scp=84921032154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921032154&partnerID=8YFLogxK

U2 - 10.1517/14656566.2015.973851

DO - 10.1517/14656566.2015.973851

M3 - Article

C2 - 25328149

AN - SCOPUS:84921032154

VL - 16

SP - 187

EP - 203

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 2

ER -